Aurobindo facility receives Form 483 over procedural issues

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/ Ildo Frazao)
(Image: Getty/ Ildo Frazao)

Related tags: Form 483, Aurobindo, Manufacturing, India, Fda, Injectables

US FDA issues Form 483 to Aurobindo’s drug product manufacturing plant after it failed to follow sterile procedures.

The Form 483 comes after the US Food and Drug Administration (FDA) conducted an inspection at the facility in Hyderabad, India, in December 2018. During the inspection, the agency noticed that procedures to prevent microbiological contamination of drug products were not followed.

Only two observations were made, but the FDA’s report spans twelve-pages – detailing improper set-up of lines for aseptic filling of drug products for the US drug market and the mishandling of primary packaging components.

The first observation stated that active-air sample results from the aseptic filling line could not be assured of presenting proper air quality throughout the filling. It also noted that procedures for air monitoring using the settling plates to monitor the filling area were not at working level.  

The second observation of the two is in regards to protective apparel that is to be worn to protect drug products from contamination. Operators provided no assurance that the required apparel is worn in the aseptic production areas, which could lead to possible contamination.

In March 2018, the same injectables facility received nine observations​ from the FDA, including signs of rodents and insects.

Another Aurobindo facility was issued a Form 483 regarding procedural issues in September 2017. The antibiotics manufacturing facility​ in Andhra Pradesh, India, received a Form 483 after the FDA observed a lack of written produces to assure strength, quality, purity, and drug identity.

Related news

Show more

Related products

show more

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Strategies to Achieve Successful Approval & Launch

Strategies to Achieve Successful Approval & Launch

Catalent Pharma Solutions | 03-Sep-2020 | Data Sheet

There are several key considerations to how companies should approach commercial-scale manufacturing that may aid the success of their biologic’s launch...

Lactium, your ally to manage day to day stress

Lactium, your ally to manage day to day stress

Ingredia | 27-Aug-2020 | Product Presentation

Stress has been called the ‘health epidemic of the 21st century’ by the World Health Organization. Increasingly, consumers are looking for safe, reliable...

Related suppliers

Follow us

Products

View more

Webinars